Notícias

Sale follows 30% rebound in the stock year to date.

AI adoption is reshaping medical devices, with ISRG, TEM and TMO leveraging AI to advance precision medicine and drug development.

Goldman Sachs’ Neutral initiation of Tempus AI, Inc. (NASDAQ:TEM) on September 21 puts the company’s fastest-growing businesses under different tests: diagnostics offers visible near-term growth, while the data and applications segment faces renewal risk as several major contracts approach extensions over the next two years. The timing is notable because Tempus AI, Inc. (NASDAQ:TEM) announced […]

Tempus AI (NASDAQ:TEM) Founder and CEO Eric Lefkofsky said the company’s second-quarter performance was supported by continued demand for comprehensive genomic profiling and growth in its data-licensing business. Speaking at Morgan Stanley’s Global Healthcare Conference, Lefkofsky said the diagnost

On September 9, Tempus AI (NASDAQ:TEM) said ARPA-H, a US health research agency, picked it to build an AI that treats heart failure patients without a clinician stepping in. The award is worth up to $9.5 million, which is small change for a company booking hundreds of millions in quarterly sales. But the dollars are […]

Tempus AI (TEM) has put a new data project at the center of the story. The business plans a research platform built on 100,000 whole genomes linked to long term clinical records. Tempus AI’s new whole genome project arrives after a sharp run in the shares, with a 90 day share price return of 62.68% and a 7 day gain of 31.91%. However, the 1 year total shareholder return of an 11.79% decline shows the longer term picture has been more mixed despite the current momentum around the US$77.84...

Earlier this month, Tempus AI announced a multi‑year initiative to build a research platform of 100,000 whole genomes linked to longitudinal clinical, imaging, pathology and outcome data, with plans to eventually scale toward one million genomes and offer broad access via its Tempus Lens environment by mid‑2027. This move extends Tempus AI beyond targeted panels into whole‑genome sequencing, creating a model‑ready, multimodal dataset specifically tailored for AI‑driven disease and drug...

Tempus AI (NasdaqGS:TEM) announced a new whole-genome sequencing initiative linked to clinical data for AI research in September 2026. The project aims to create a de-identified multimodal dataset that connects full genome reads with real-world clinical and imaging records. Management targets scaling the platform to one million whole genomes tied to patient outcomes for use in drug development and personalized care. This new whole-genome sequencing and clinical data platform comes against a...

Cathie Wood's ARK Invest funds made a broad move out of crypto-linked assets during the week, led by the sale of more than 1.5 million shares of the ARK 21Shares Bitcoin ETF.

Tempus (TEM) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.

NVIDIA, Advanced Micro Devices, Tempus, Moderna, Super Micro Computer and Aya Gold & Silver have been highlighted in this Investment Ideas article.

While macroeconomic headwinds, geopolitical energy shocks, and relentless media fear-mongering might suggest a market correction is overdue, the resilience of stock price action tells a different story.

Clarity on how much revenue Tempus AI will bring in through Medicare reimbursements for two of its cancer screenings appeased investors this week as shares surged Thursday. Tempus stock added 15% Thursday as part of a 36% advance over the last five sessions. in which Tempus is the third-largest position behind Tesla and SpaceX rose 4.3%.

Morgan Stanley just reframed the revenue story for Tempus AI in a way that management's own guidance never fully captured, and the market is now scrambling to catch up with what reimbursement clarity actually means for the bottom line.

Cathie Wood's firm ARK Invest added to its already sizable position in the trading platform Robinhood, which is back in a buy zone.

Personalized cancer vaccines are creating a diagnostics investment opportunity beyond Moderna and Merck, with tumor sequencing at its center.

Tempus AI could capture a lucrative slice of Moderna and Merck’s personalized cancer therapy business, with Personalis at the center of the bet.

Tempus AI received a fresh vote of confidence on September 2 as Cantor Fitzgerald initiated coverage with an Overweight rating and an $80 price target. From the roughly $62.27 price cited with the call, that implied about 28% upside. The argument centers on a difficult-to-replicate combination: clinical data, diagnostics, software, and artificial intelligence operating inside […]

With central banks lifting interest rates to tackle inflation, investors are hunting for themes that do not rely purely on cheap money to grow. Artificial intelligence in healthcare is one such story. It focuses on software and data rather than heavy assets. This article highlights three Transformative AI Healthcare Stocks from our screener that apply algorithms to diagnostics, treatment decisions, and hospital efficiency. The three stocks that follow are only a starting sample from this...

Sirius XM upgraded, Toast downgraded: Wall Street's top analyst calls

Sale executed under pre-established Rule 10b5-1 trading plan adopted in May, leaving West with 31,981 shares and a 0.0183% ownership stake.

ARK shifted more than $50 million into Block and Rocket Lab while trimming several high-profile growth names.

Personalis holders receive Tempus shares worth $16.25 each under the pending merger

Robinhood upgraded, Uber initiated: Wall Street's top analyst calls

Tempus AI (NASDAQ:TEM) shares rose 2. 7% in pre-market trading following analyst actions from Piper Sandler and Canaccord Genuity as investors assessed the company’s pending acquisition of Personalis.

Nvidia was ARK’s biggest August purchase, with roughly 548,000 shares added during the month.

Tempus AI, Inc. (NASDAQ:TEM) rallied following a melanoma breakthrough reported by Moderna and Merck. The companies said their Phase 3 INTerpath-001 trial met its recurrence-free survival endpoint for the personalized cancer therapy intismeran autogene, also known as V940, combined with Keytruda. Detailed trial data remain pending. The read-through came from Personalis, which has supported the […]

Here are Cathie Wood’s latest moves.

Tempus AI (NasdaqGS:TEM) received FDA 510(k) clearance for Tempus ECG-PH, an AI-enabled tool that flags signs of pulmonary hypertension from standard ECGs. The newly cleared product is the third FDA-cleared offering in Tempus AI's cardiovascular portfolio, expanding the company beyond its core oncology genomics focus. Tempus ECG-PH is designed to help clinicians identify a condition that can be challenging to diagnose using conventional methods, addressing a key unmet need in cardiovascular...

An AI stock sits in Nancy Pelosi’s stock portfolio and has slid this year. Here’s what her trades and Q2 earnings suggest is next.